295 related articles for article (PubMed ID: 15531016)
1. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project).
Cutrer FM; Goadsby PJ; Ferrari MD; Lipton RB; Dodick DW; McCrory D; Williams P
Clin Ther; 2004 Sep; 26(9):1533-45. PubMed ID: 15531016
[TBL] [Abstract][Full Text] [Related]
2. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians.
Lipton RB; Cutrer FM; Goadsby PJ; Ferrari MD; Dodick DW; McCrory D; Liberman JN; Williams P
Curr Med Res Opin; 2005 Mar; 21(3):413-24. PubMed ID: 15811210
[TBL] [Abstract][Full Text] [Related]
3. TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management.
Goadsby PJ; Dodick DW; Ferrari MD; McCrory DC; Williams P
Acta Neurol Scand; 2004 Sep; 110(3):137-43. PubMed ID: 15285768
[TBL] [Abstract][Full Text] [Related]
4. Almotriptan: meeting today's needs in acute migraine treatment.
Láinez MJ
Expert Rev Neurother; 2007 Dec; 7(12):1659-73. PubMed ID: 18052762
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials.
Belsey JD
Curr Med Res Opin; 2004 May; 20(5):659-69. PubMed ID: 15140331
[TBL] [Abstract][Full Text] [Related]
6. Economic comparison of oral triptans for management of acute migraine: implications for managed care.
Reeder CE; Steadman S; Goldfarb SD
Am J Manag Care; 2002 Feb; 8(3 Suppl):S80-4. PubMed ID: 11859908
[TBL] [Abstract][Full Text] [Related]
7. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.
Sheftell FD; Feleppa M; Tepper SJ; Volcy M; Rapoport AM; Bigal ME
Headache; 2004; 44(7):661-8. PubMed ID: 15209687
[TBL] [Abstract][Full Text] [Related]
8. Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project.
Dodick DW; Lipton RB; Ferrari MD; Goadsby PJ; McCrory D; Cutrer FM; Williams P
Curr Pain Headache Rep; 2004 Dec; 8(6):435-42. PubMed ID: 15509456
[TBL] [Abstract][Full Text] [Related]
9. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls.
Loder E; Goldstein R; Biondi D
Cephalalgia; 2005 Feb; 25(2):124-31. PubMed ID: 15658949
[TBL] [Abstract][Full Text] [Related]
10. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
[TBL] [Abstract][Full Text] [Related]
11. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine.
Chen LC; Ashcroft DM
Headache; 2008 Feb; 48(2):236-47. PubMed ID: 18179569
[TBL] [Abstract][Full Text] [Related]
13. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
Bell CF; Foley KA; Barlas S; Solomon G; Hu XH
Clin Ther; 2006 Jun; 28(6):872-80. PubMed ID: 16860170
[TBL] [Abstract][Full Text] [Related]
14. Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials.
Dahlöf CG
Cephalalgia; 2006 Feb; 26(2):98-106. PubMed ID: 16426262
[TBL] [Abstract][Full Text] [Related]
15. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.
Ferrari MD; Roon KI; Lipton RB; Goadsby PJ
Lancet; 2001 Nov; 358(9294):1668-75. PubMed ID: 11728541
[TBL] [Abstract][Full Text] [Related]
16. Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study.
Cady R; Martin V; Adelman J; Diamond M; Sajjan S; Hu XH
Headache; 2004 Oct; 44(9):900-7. PubMed ID: 15447699
[TBL] [Abstract][Full Text] [Related]
17. A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy.
Gori S; Morelli N; Acuto G; Caiola F; Iudice A; Murri L
Minerva Med; 2006 Dec; 97(6):467-77. PubMed ID: 17213783
[TBL] [Abstract][Full Text] [Related]
18. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.
Ferrari MD; Goadsby PJ; Roon KI; Lipton RB
Cephalalgia; 2002 Oct; 22(8):633-58. PubMed ID: 12383060
[TBL] [Abstract][Full Text] [Related]
19. Almotriptan versus sumatriptan in migraine treatment: direct medical costs of managing adverse chest symptoms.
Mannix LK; Adelman JU; Goldfarb SD; Von S; Kozma CM
Am J Manag Care; 2002 Feb; 8(3 Suppl):S94-101. PubMed ID: 11859910
[TBL] [Abstract][Full Text] [Related]
20. Almotriptan: a review of pharmacology, clinical efficacy, and tolerability.
Von S
Am J Manag Care; 2002 Feb; 8(3 Suppl):S74-9. PubMed ID: 11859907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
